MX348412B - Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2. - Google Patents

Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.

Info

Publication number
MX348412B
MX348412B MX2011008994A MX2011008994A MX348412B MX 348412 B MX348412 B MX 348412B MX 2011008994 A MX2011008994 A MX 2011008994A MX 2011008994 A MX2011008994 A MX 2011008994A MX 348412 B MX348412 B MX 348412B
Authority
MX
Mexico
Prior art keywords
sns
methods
treatment
cancer subjects
brca2 activity
Prior art date
Application number
MX2011008994A
Other languages
English (en)
Other versions
MX2011008994A (es
Inventor
E Hawtin Rachael
A Fox Judith
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of MX2011008994A publication Critical patent/MX2011008994A/es
Publication of MX348412B publication Critical patent/MX348412B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

La presente invención se refiere a métodos de usar SNS-595 para el tratamiento de un sujeto que tiene cáncer con mutación de BRCA2. En ciertas modalidades, los métodos comprenden administrar una cantidad terapéuticamente efectiva de SNS-595 a un sujeto en necesidad del mismo.
MX2011008994A 2009-02-27 2010-03-01 Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2. MX348412B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15644909P 2009-02-27 2009-02-27
US17001309P 2009-04-16 2009-04-16
PCT/US2010/025737 WO2010099526A1 (en) 2009-02-27 2010-03-01 Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity

Publications (2)

Publication Number Publication Date
MX2011008994A MX2011008994A (es) 2011-09-15
MX348412B true MX348412B (es) 2017-06-12

Family

ID=42224275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008994A MX348412B (es) 2009-02-27 2010-03-01 Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.

Country Status (14)

Country Link
US (3) US20120148564A1 (es)
EP (2) EP3287126A1 (es)
JP (2) JP5936862B2 (es)
KR (2) KR20110132400A (es)
CN (2) CN102405045A (es)
AU (2) AU2010217796B2 (es)
CA (1) CA2753261A1 (es)
IL (1) IL214784A0 (es)
MX (1) MX348412B (es)
NZ (1) NZ594829A (es)
RU (1) RU2558835C2 (es)
SG (2) SG173855A1 (es)
WO (1) WO2010099526A1 (es)
ZA (1) ZA201106199B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1729770E (pt) 2004-03-15 2010-02-08 Sunesis Pharmaceuticals Inc Sns-595 e métodos de utilização do mesmo
US8518872B2 (en) 2007-10-22 2013-08-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
UA108194C2 (uk) 2008-12-31 2015-04-10 Спосіб отримання (+)-1,4-дигідро-7-[(3s,4s)-3-метокси-4-(метиламіно)-1-піролідиніл]-4-оксо-1-(2-тіазоліл)-1,8-нафтиридин-3-карбонової кислоти
US20120148564A1 (en) * 2009-02-27 2012-06-14 Hawtin Rachael E Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
WO2011056566A2 (en) 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2023110045A1 (en) 2021-12-15 2023-06-22 Y-Mabs Therapeutics, Inc. Scfv and antibodies with reduced multimerisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024A (en) * 1849-01-09 Cast-iron gar-wheel
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
DE69524251T2 (de) 1994-06-14 2002-07-11 Dainippon Pharmaceutical Co Neue verbindung, verfahren zu ihrer herstellung und antitumormittel
JPH10173986A (ja) 1996-12-16 1998-06-26 Sony Corp 移動体撮影装置
CN102107008B (zh) * 2003-12-01 2013-04-03 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
PT1729770E (pt) 2004-03-15 2010-02-08 Sunesis Pharmaceuticals Inc Sns-595 e métodos de utilização do mesmo
EP1931339B1 (en) * 2005-09-02 2018-05-16 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
JP2009539994A (ja) 2006-06-12 2009-11-19 サネシス ファーマシューティカルズ， インコーポレイテッド 癌の治療のための化合物及び組成物
US7790274B2 (en) 2006-08-02 2010-09-07 High Impact Technology, Llc Layered panel structure including self-bonded thermoformable and non-thermoformable layer materials
EP2155897A2 (en) * 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
US20120148564A1 (en) * 2009-02-27 2012-06-14 Hawtin Rachael E Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity

Also Published As

Publication number Publication date
SG173855A1 (en) 2011-09-29
US20120148564A1 (en) 2012-06-14
JP2012523376A (ja) 2012-10-04
KR20170046193A (ko) 2017-04-28
US20150202189A1 (en) 2015-07-23
SG10201400258SA (en) 2014-05-29
CN104688732A (zh) 2015-06-10
CN102405045A (zh) 2012-04-04
MX2011008994A (es) 2011-09-15
KR20110132400A (ko) 2011-12-07
NZ594829A (en) 2013-09-27
AU2010217796B2 (en) 2015-04-30
RU2011139323A (ru) 2013-04-10
IL214784A0 (en) 2011-11-30
AU2010217796A1 (en) 2011-09-15
JP5936862B2 (ja) 2016-06-22
CA2753261A1 (en) 2010-09-02
ZA201106199B (en) 2012-10-31
EP2400959A1 (en) 2012-01-04
US20170182015A1 (en) 2017-06-29
RU2558835C2 (ru) 2015-08-10
JP2015145396A (ja) 2015-08-13
WO2010099526A1 (en) 2010-09-02
EP3287126A1 (en) 2018-02-28
AU2015207901A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
PH12017501419B1 (en) Therapeutically active compounds and their methods of use
AU2011328009A8 (en) Compounds and methods for treating pain
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
MX342951B (es) Composiciones terapeuticamente activas y su metodo de uso.
MX350432B (es) Compuestos terapeuticamente activos y sus metodos de empleo.
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
MX2009003362A (es) Uso de interleucina-10 pegilada para tratamiento de cancer.
MX2011008221A (es) Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
NZ631144A (en) Compositions and methods for transmucosal absorption
MX350539B (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
MX2013003076A (es) Terapeuticos contra cancer de mama.
TN2011000403A1 (en) Compositions and methods for extended therapy wiht aminopyridines
TW201611843A (en) Methods of treatment with arginine deiminase
MX353964B (es) Agentes terapeuticos y usos de los mismos.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
PH12015501002A1 (en) Treatment of cancer with pomalidomide in a renally impaired subject
IL207310A0 (en) Vaccine compositions
MX354383B (es) Sistemas, métodos y formulaciones para tratamiento de cáncer.
IN2012DN02195A (es)
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma

Legal Events

Date Code Title Description
FG Grant or registration